Field & Main Bank Purchases 668 Shares of Eli Lilly and Company (NYSE:LLY)

Field & Main Bank boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,722 shares of the company’s stock after acquiring an additional 668 shares during the period. Eli Lilly and Company accounts for 1.9% of Field & Main Bank’s investment portfolio, making the stock its 11th biggest holding. Field & Main Bank’s holdings in Eli Lilly and Company were worth $4,501,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $27,000. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $35,000. Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $40,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 0.5 %

NYSE LLY traded up $3.82 during trading on Monday, hitting $737.33. The stock had a trading volume of 2,726,536 shares, compared to its average volume of 3,017,770. Eli Lilly and Company has a 12 month low of $392.26 and a 12 month high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company’s 50-day moving average price is $760.89 and its two-hundred day moving average price is $668.00. The company has a market capitalization of $700.58 billion, a PE ratio of 127.13, a P/E/G ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue was up 28.1% compared to the same quarter last year. During the same period last year, the company earned $2.09 earnings per share. As a group, sell-side analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on LLY shares. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Bank of America raised their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. BMO Capital Markets upped their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Finally, DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research report on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.